Clinical Trials
3 trialsNCT05825365 2023-08-14
PROTECT
AstraZeneca
Phase 2 Withdrawn
NCT03688568 2021-02-12
Study of Imatinib in Children With Neurofibromatosis and Airway Tumors
Indiana University
Phase 2 Withdrawn
NCT03109301 2019-04-05
Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn